Our performance & strategy
2025 Annual Report
In 2025, Telix continued to deliver strong revenue growth while investing in its supply chain and progressing its pipeline of therapeutic candidates. These investments have transformed the Company, positioning it for sustainable, long-term growth, while its diversified business provides multiple opportunities for geographic and product
expansion.
Message from the Chair (Interim)
“Telix is now a global radiopharmaceutical company with a specialist commercial organization and fully integrated radiopharma company, assisted by our acquisition of RLS Radiopharmacies during the year.”
Message from the CEO
“Telix remains strongly positioned for long-term growth, driven by scientific excellence and an unwavering commitment to improving patient outcomes worldwide.”
Our commercial and clinical focus
Financial review
Renumeration report
Sustainability report
FORM 20-F